Previous Close | 97.24 |
Open | 96.86 |
Bid | 97.09 x 90000 |
Ask | 97.39 x 90000 |
Day's Range | 96.86 - 96.99 |
52 Week Range | 85.41 - 111.18 |
Volume | |
Avg. Volume | 135 |
Market Cap | 169.024B |
Beta (5Y Monthly) | 0.75 |
PE Ratio (TTM) | 32.55 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.07 (2.13%) |
Ex-Dividend Date | Apr 12, 2024 |
1y Target Est | N/A |
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ...
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.